home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> mail archive   |   Search register for news alert (free)  
  Hans Goerl: ETHI, DIAG: genetic testing  

archive of HUM-MOLGEN mails


[Author Prev][Author Next][Thread Prev][Thread Next][Author Index][Topic Index]

To: Multiple recipients of list HUM-MOLGEN <HUM-MOLGEN@NIC.SURFNET.NL>
Subject: ETHI, DIAG: genetic testing
From: Hans Goerl <GENETHICS@delphi.com>
Date: Sat, 16 Sep 1995 14:15:04 -0400

The following press releases should be considered  in the light of the
recently posted report of the first meeting of the NIH Task Force on Genetic
Testing. My apologies to all for the formatting.

Hans Goerl
ETHI editor


 Oncor, Inc. announced today that it has received permission from the U.S.
Food and Drug Administration (FDA) to export its investigational in vitro
diagnostic genetic test systems for HER-2/neu and Chronic Myelogenous
Leukemia (CML) Mbcrlabl to Austria, Switzerland, and Ireland. Applications
for permission to export these systems to other European countries are
pending.     The two in vitro diagnostic test kits completed multi-center
clinical investigations and are currently undergoing review for pre- market
approval at the FDA.  Oncor anticipates an FDA panel review will be
scheduled during the fourth quarter of 1995 for its HER-2/neu (ERBB2) Gene
Amplification Detection System for the characterization and management of
breast cancer.  Oncor filed a PMA application with the FDA for the test
system in February 1994.     Oncor, Inc. (http://www.oncorinc.com/home)
develops, manufactures and markets genetic test systems and related products
 for use in the detection and management of cancer and other human disease.



Date: Tue, Sep 12, 1995
     Bayer Corporation and Myriad Genetics, Inc., today jointly announced a
five-year strategic alliance focused on the discovery of genes which
predispose individuals to obesity, osteoporosis and asthma.  The
collaboration will combine Myriad's strengths in gene discovery and gene
characterization with Bayer's drug discovery, development and marketing
     Myriad received a $10 million equity investment from Bayer
and, under the terms of the agreement, will receive $25 million in research
payments over the five year period.  In addition, Bayer will provide Myriad
with up to $36 million in milestone payments for the discovery and
characterization of genes related to obesity, osteoporosis and asthma.  In
exchange for future royalty payments to Myriad, Bayer will receive a
worldwide exclusive license to develop and commercialize therapeutic
products derived from the collaboration, including small- molecule, protein
replacement and gene therapeutics.  Myriad will retain worldwide diagnostic
rights, including the right to develop and market genetic tests that screen
for genes which predispose patients to obesity, osteoporosis and asthma.
     "Our alliance with Myriad is a key component of our efforts to utilize

molecular genetics in Bayer's pharmaceutical discovery program. Myriad has
developed an impressive set of technologies for genetic discovery and is a
leader in locating and sequencing important disease- related genes," said
Horst Wallrabe, Executive Vice President, Bayer Corporation and President of
 Bayer's Pharmaceutical Division.  "We look forward to collaborating with

Myriad and pursuing the development of important and innovative therapies."
    Molecular genetics involves isolating genes and identifying the genetic

mutations involved in predisposing individuals to a particular disorder.
Understanding the genetic basis of disease may provide critical tools for
analyzing the molecular pathways in the disease process, and helps define
new targets against which innovative therapies can be designed.
     Peter D. Meldrum, President and CEO of Myriad, commented: "Bayer is a
leader in the development and marketing of pharmaceutical products for
metabolic and respiratory disorders.  Bayer's participation in this
agreement underscores our strength in gene discovery and the potential for
advancing drug discovery using Myriad's technologies.  Our collaboration
with Bayer furthers Myriad's strategy of capitalizing on strategic alliances
to develop
therapeutic products based on our gene discoveries while retaining exclusive
 rights to commercialize genetic testing products and services."


     Myriad Genetics, Inc., based in Salt Lake City, Utah, is a gene
discovery and genetic testing company focused on the discovery and
commercialization of genes involved in major common disorders, including
cancer, heart disease, obesity, osteoporosis and asthma.  Myriad is
currently establishing a genetic testing and information business through
its wholly owned subsidiary, Myriad Genetic Laboratories, Inc.     In order
to accelerate its gene discovery programs, Myriad employs two synergistic
sets of technologies: the genetic analysis of large families performed by
Myriad's scientists and collaborators; and Myriad's advanced, proprietary
gene mapping, sequencing and cloning technologies.  This combined approach
provides an unparalleled resource in the gene discovery process and allows
for the rapid discovery of important disease-causing genes, as well as the
characterization of harmful mutations in those genes.  Using this strategy,
Myriad has made several major genetic discoveries during the last 18 months,
 including the BRCA1 breast and ovarian cancer gene and the role of the MTS1

gene in many cancer types.

The Company intends to commercialize its gene discoveries by providing
genetic tests for individuals to determine whether or not they have
inherited gene mutations which may increase their risk for specific
diseases.  Myriad has developed a highly automated genetic testing platform
which the Company believes will enable it, once it has discovered and
sequenced a gene, to develop a test for genetic predisposition relatively
quickly and economically.

The Company believes that the
information gained from the tests that confirm genetic predisposition has
potential value to individuals and their health care providers in the
following areas: (i) proactive health care and lifestyle decisions that may
delay or prevent the onset of disease; (ii) early detection of disease; and
(iii) selection of the most appropriate treatment.

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Mail converted by MHonArc 2.4.4
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.